Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
J.J. Schentag.
Correlation of pharmacokinetic parameters to efficacy of antibiotics: relationships between serum concentration, MIC values, and bacterial eradication in patients with gram-negative pneumonia.
Scand J Infect Dis, 74 (1991), pp. 218-234
[2.]
R. Ismail, A.H. Haq, M. Azman, A.F. Rahman.
Therapeutic drug monitoring of gentamicin: a 6 year follow up audit.
J Clin Pharm Ther, 22 (1999), pp. 21-25
[3.]
A.P. MacGowan.
Pharmacodynamics, pharmacokinetics, and therapeutic drug monitoring of glycopeptides.
Ther Drug Monit, 20 (1998), pp. 473-477
[4.]
M.V. Miles, L. Li, H. Lakkis, J. Youngblood, P. McGinnis.
Special considerations for monitoring vancomycin concentrations in pediatric patients.
Ther Drug Monit, 19 (1997), pp. 265-270
[5.]
G. Lugo Goytia, I. Lares-Asseff, M.G. Pérez Guille, A.G. Pérez, C.L. Mejia.
Relationship between clinical and biologic variables and chloramphenicol pharmacokinetic parameters in pediatric patients with sepsis.
Ann Pharmacother, 34 (2000), pp. 393-397
[6.]
W.A. Craig.
Pharmacokinetic/pharmacodiynamic parametres: rationale for antibacterial dosing of mice and men.
Clin Infect Dis, 26 (1998), pp. 1-12
[7.]
C.R. Marchbanks, J.R. McKiel, D.H. Gilbert, N.J. Robillard, B. Painter, S.H. Zinner, M.N. Dudley.
Dose ranging and fractionation of intravenous ciprofloxacin against Pseudomonas aeruginosa and Staphylococcus aureus in a in vitro model of infection.
Antimicrob Agents Chemother, 37 (1993), pp. 1.756-1.763
[8.]
K.J. Madaras-Kelly, B.E. Ostergaard, L.B. Hovde, J.C. Rotschafer.
Twentyfour-hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model.
Antimicrob Agents Chemother, 40 (1996), pp. 627-632
[9.]
R.C. Li, Z.Y. Zhu, S.W. Lee, K. Raymond, J.M. Ling, A.F.B. Cheng.
Antibiotic exposure and its relationship to postantibiotic effect and bactericidal activity: constant versus exponentially decreasing tobramycin concentrations against Pseudomonas aeruginosa.
Antimicrob Agents Chemother, 41 (1997), pp. 1.808-1.811
[10.]
M.L. Barclay, E.J. Begg.
Aminoglycoside adaptive resistance: importance for effective dosage regimens.
Drugs, 61 (2001), pp. 713-721
[11.]
M.J. Bouvier d’Yvoire, P.H. Taubert.
Dosage regimens of antibacterials: implications of a pharmacokinetic/pharmacodynamic model.
Clin Drug Invest, 11 (1996), pp. 229-239
[12.]
J. Lipman, C.D. Gomersall, T. Gin, G.M. Joynt, R.J. Young.
Continuous infusion ceftazidime in intensive care: a randomized controlled trial.
J Antimicrob Chemother, 43 (1999), pp. 309-311
[13.]
C.O. Onyeji, D.P. Nicolau, C.H. Nightingale, R. Quintiliani.
Optimal times above MICs of ceftibuten and cefaclor in experimentl intra-abdominal infection.
Antimicrob Agents Chemother, 38 (1994), pp. 1.112-1.117
[14.]
M. Manduru, L.B. Mihm, L.V. Friedrich, P.A. Flume, J.A. Bosso.
In vitro pharmacodynamics of ceftazidime against Pseudomonas aeruginosa isolates from cystic fibrosis patients.
Antimicrob Agents Chemother, 41 (1997), pp. 2.053-2.056
[15.]
J.Q. Tran, C.H. Ballow, A. Forrest, J.M. Hyatt, M.F. Sands, C.A. Peloquin, J.J. Schentag.
Comparison of the abilities of grepafloxacin and clarithromycin to eradicate potential bacterial pathogens from the sputa of patients with chronic bronchitis: influence of pharmacokinetic and pharmacodynamic variables.
J Antimicrob Chemother, 45 (2000), pp. 9-17
[16.]
W.A. Craig, D. Andes.
Pharmacokinetics and pharmacodynamics of antibiotics in otitis media.
Pediatric Infect Dis J, 15 (1996), pp. 255-259
Copyright © 2001. Elsevier España, S.L.. Todos los derechos reservados
